$REGN
REGENERON PHARMACEUTICALS, INC.

2014 Q1 Form 10-Q Financial Statement

#000153217614000022 Filed on May 08, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 Q1
Revenue $625.7M $439.7M
YoY Change 42.32% 89.68%
Cost Of Revenue $27.47M $28.02M
YoY Change -1.96% 127.85%
Gross Profit $598.3M $411.6M
YoY Change 45.34% 87.54%
Gross Profit Margin 95.61% 93.63%
Selling, General & Admin $103.2M $77.26M
YoY Change 33.61% 32.23%
% of Gross Profit 17.25% 18.77%
Research & Development $287.4M $180.3M
YoY Change 59.39% 29.84%
% of Gross Profit 48.04% 43.8%
Depreciation & Amortization $11.53M $9.407M
YoY Change 22.57% 11.78%
% of Gross Profit 1.93% 2.29%
Operating Expenses $390.6M $257.6M
YoY Change 51.66% 30.55%
Operating Profit $191.6M $153.1M
YoY Change 25.16% 589.38%
Interest Expense $11.61M $11.68M
YoY Change -0.53% 4.61%
% of Operating Profit 6.06% 7.63%
Other Income/Expense, Net -$10.68M -$11.22M
YoY Change -4.84% 6.34%
Pretax Income $180.9M $141.8M
YoY Change 27.54% 1117.33%
Income Tax $112.6M $42.96M
% Of Pretax Income 62.24% 30.29%
Net Earnings $68.31M $98.87M
YoY Change -30.92% 748.63%
Net Earnings / Revenue 10.92% 22.49%
Basic Earnings Per Share $0.69 $1.02
Diluted Earnings Per Share $0.61 $0.90
COMMON SHARES
Basic Shares Outstanding 98.71M shares 96.88M shares
Diluted Shares Outstanding 112.2M shares 109.4M shares

Balance Sheet

Concept 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $648.0M $308.0M
YoY Change 110.39% -28.7%
Cash & Equivalents $461.9M $180.4M
Short-Term Investments $186.0M $127.0M
Other Short-Term Assets $107.0M $159.0M
YoY Change -32.7% -16000.0%
Inventory $86.55M $43.98M
Prepaid Expenses
Receivables $801.8M $703.9M
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.871B $1.307B
YoY Change 43.14% 87.54%
LONG-TERM ASSETS
Property, Plant & Equipment $600.9M $392.4M
YoY Change 53.13% 6.05%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $535.0M $347.0M
YoY Change 54.18% 36.08%
Other Assets $5.340M $20.08M
YoY Change -73.4% -30.77%
Total Long-Term Assets $1.389B $968.9M
YoY Change 43.4% 48.37%
TOTAL ASSETS
Total Short-Term Assets $1.871B $1.307B
Total Long-Term Assets $1.389B $968.9M
Total Assets $3.260B $2.276B
YoY Change 43.25% 68.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $33.00M $25.00M
YoY Change 32.0% 0.0%
Accrued Expenses $205.0M $121.0M
YoY Change 69.42% 49.38%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $305.1M $197.2M
YoY Change 54.67% 23.28%
LONG-TERM LIABILITIES
Long-Term Debt $530.0M $461.0M
YoY Change 14.97% 4.77%
Other Long-Term Liabilities $11.79M $8.786M
YoY Change 34.24% -96.43%
Total Long-Term Liabilities $11.79M $8.786M
YoY Change 34.24% -98.72%
TOTAL LIABILITIES
Total Short-Term Liabilities $305.1M $197.2M
Total Long-Term Liabilities $11.79M $8.786M
Total Liabilities $1.049B $869.7M
YoY Change 20.64% 2.8%
SHAREHOLDERS EQUITY
Retained Earnings -$27.25M -$418.2M
YoY Change -93.48%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.211B $1.406B
YoY Change
Total Liabilities & Shareholders Equity $3.260B $2.276B
YoY Change 43.25% 68.59%

Cashflow Statement

Concept 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income $68.31M $98.87M
YoY Change -30.92% 748.63%
Depreciation, Depletion And Amortization $11.53M $9.407M
YoY Change 22.57% 11.78%
Cash From Operating Activities $53.53M $86.25M
YoY Change -37.94% -199.09%
INVESTING ACTIVITIES
Capital Expenditures -$64.80M -$21.20M
YoY Change 205.66% 90.99%
Acquisitions
YoY Change
Other Investing Activities -$171.4M -$126.5M
YoY Change 35.49% -572.01%
Cash From Investing Activities -$236.2M -$147.7M
YoY Change 59.96% -1036.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $55.04M $12.96M
YoY Change 324.58% -59.27%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $109.0M $11.52M
YoY Change 845.54% -164.92%
NET CHANGE
Cash From Operating Activities $53.53M $86.25M
Cash From Investing Activities -$236.2M -$147.7M
Cash From Financing Activities $109.0M $11.52M
Net Change In Cash -$73.75M -$49.91M
YoY Change 47.75% -43.93%
FREE CASH FLOW
Cash From Operating Activities $53.53M $86.25M
Capital Expenditures -$64.80M -$21.20M
Free Cash Flow $118.3M $107.4M
YoY Change 10.12% -241.49%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
127720000 USD
CY2013Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
63189000 USD
CY2014Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
237935000 USD
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
250896000 USD
CY2014Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
32692000 USD
CY2013Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
61936000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
787071000 USD
CY2014Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
801773000 USD
CY2014Q1 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
118003000 USD
CY2013Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
104707000 USD
CY2014Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1465000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1188000 USD
CY2014Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2236931000 USD
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
2045857000 USD
CY2014Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
117260000 USD
CY2013Q1 us-gaap Adjustment To Additional Paid In Capital Income Tax Effect From Share Based Compensation Net
AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
2293000 USD
CY2013Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
3085000 USD
CY2014Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
63086000 USD
CY2014Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
82982000 USD
CY2013Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
53555000 USD
CY2014Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-11916000 USD
CY2013Q1 us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-12626000 USD
CY2013Q4 us-gaap Assets
Assets
2951013000 USD
CY2014Q1 us-gaap Assets
Assets
3260396000 USD
CY2014Q1 us-gaap Assets Current
AssetsCurrent
1871049000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
1796934000 USD
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
548267000 USD
CY2014Q1 us-gaap Available For Sale Securities
AvailableForSaleSecurities
720964000 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
548322000 USD
CY2014Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
718366000 USD
CY2014Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
0 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAggregateLosses
0 USD
CY2014Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
515000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAggregateLosses
447000 USD
CY2014Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
286344000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
239812000 USD
CY2013 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
447000 USD
CY2014Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Aggregate Losses
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses
515000 USD
CY2014Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
286344000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
239812000 USD
CY2013Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2014Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
0 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4138000 USD
CY2014Q1 us-gaap Available For Sale Securities Debt Maturities After Five Through Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
4042000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
383410000 USD
CY2014Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
525961000 USD
CY2014Q1 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
1151000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities After Ten Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
1177000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
158376000 USD
CY2014Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
186275000 USD
CY2013Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
547101000 USD
CY2014Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
717429000 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
392000 USD
CY2014Q1 us-gaap Available For Sale Securities Gross Unrealized Gains
AvailableForSaleSecuritiesGrossUnrealizedGains
3113000 USD
CY2013 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
447000 USD
CY2014Q1 us-gaap Available For Sale Securities Gross Unrealized Loss
AvailableForSaleSecuritiesGrossUnrealizedLoss
515000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
535608000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
461858000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
180362000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
230276000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-73750000 USD
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-49914000 USD
CY2013Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
98396000 USD
CY2014Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
68096000 USD
CY2014Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
326673000 USD
CY2013Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
320315000 USD
CY2013Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
28021000 USD
CY2014Q1 us-gaap Cost Of Goods Sold
CostOfGoodsSold
27473000 USD
CY2014Q1 us-gaap Costs And Expenses
CostsAndExpenses
439801000 USD
CY2013Q1 us-gaap Costs And Expenses
CostsAndExpenses
286614000 USD
CY2014Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-8522000 USD
CY2013Q1 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
39525000 USD
CY2014Q1 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
25500000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
34185000 USD
CY2014Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
53093000 USD
CY2014Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
128539000 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
107677000 USD
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
44677000 USD
CY2014Q1 us-gaap Deferred Tax Assets Liabilities Net Current
DeferredTaxAssetsLiabilitiesNetCurrent
36623000 USD
CY2013Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
231878000 USD
CY2014Q1 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
248454000 USD
CY2013Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9407000 USD
CY2014Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
11530000 USD
CY2014Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.66
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.02
CY2014Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.58
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.90
CY2013Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.303
CY2014Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.627
CY2014Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.104
CY2014Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.000
CY2013Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.123
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
69429000 USD
CY2014Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
41754000 USD
CY2014Q1 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
117260000 USD
CY2013Q1 us-gaap Excess Tax Benefit From Share Based Compensation Financing Activities
ExcessTaxBenefitFromShareBasedCompensationFinancingActivities
2293000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
175263000 USD
CY2013Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
141831000 USD
CY2013Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42957000 USD
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
109820000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-14139000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
32105000 USD
CY2013Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
117782000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
92529000 USD
CY2014Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
37107000 USD
CY2013Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-6470000 USD
CY2014Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
15550000 USD
CY2013Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
17581000 USD
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
17815000 USD
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
20898000 USD
CY2014Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
3162000 shares
CY2013Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1890000 shares
CY2013Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10276000 shares
CY2014Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9879000 shares
CY2013Q1 us-gaap Interest Expense
InterestExpense
11675000 USD
CY2014Q1 us-gaap Interest Expense
InterestExpense
11613000 USD
CY2014Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
13230000 USD
CY2013Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
14352000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
70354000 USD
CY2014Q1 us-gaap Inventory Net
InventoryNet
86545000 USD
CY2014Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
6792000 USD
CY2013Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
9120000 USD
CY2013Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
35868000 USD
CY2014Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
47858000 USD
CY2013 us-gaap Inventory Write Down
InventoryWriteDown
3200000 USD
CY2014Q1 us-gaap Inventory Write Down
InventoryWriteDown
1100000 USD
CY2013Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
456000 USD
CY2014Q1 us-gaap Investment Income Nonoperating
InvestmentIncomeNonoperating
937000 USD
CY2014Q1 us-gaap Liabilities
Liabilities
1049148000 USD
CY2013Q4 us-gaap Liabilities
Liabilities
998937000 USD
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3260396000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2951013000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
298835000 USD
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
305068000 USD
CY2013Q1 us-gaap Licenses Revenue
LicensesRevenue
6744000 USD
CY2014Q1 us-gaap Licenses Revenue
LicensesRevenue
7542000 USD
CY2014Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
186275000 USD
CY2013Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
158376000 USD
CY2013Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
389891000 USD
CY2014Q1 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
534689000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
11523000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
108954000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-147685000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-236231000 USD
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
86248000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
53527000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
65443000 USD
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
98874000 USD
CY2013Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-11219000 USD
CY2014Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10676000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
185939000 USD
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
153050000 USD
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
29022000 USD
CY2014Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
38107000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5327000 USD
CY2014Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5340000 USD
CY2014Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2653000 USD
CY2013Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-478000 USD
CY2014Q1 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
18665000 USD
CY2013Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
11014000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11330000 USD
CY2014Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
11794000 USD
CY2013Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
5781000 USD
CY2014Q1 us-gaap Other Noncash Expense
OtherNoncashExpense
5916000 USD
CY2014Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3761000 USD
CY2013Q1 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-7174000 USD
CY2014Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
63086000 USD
CY2013Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
3085000 USD
CY2013Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
181236000 USD
CY2014Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
253878000 USD
CY2013Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
21203000 USD
CY2014Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
64822000 USD
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
52252000 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
32952000 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
55042000 USD
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12964000 USD
CY2014Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
82469000 USD
CY2013Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
54754000 USD
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
600864000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
526983000 USD
CY2013Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
649000 USD
CY2014Q1 us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
262000 USD
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
180299000 USD
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
287379000 USD
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-27249000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92692000 USD
CY2013Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
99273000 USD
CY2014Q1 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
130508000 USD
CY2014Q1 us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks under governmental programs (including Medicaid), distribution-related fees, prompt pay discounts, and other sales-related deductions. </font></div></div>
CY2013Q1 us-gaap Revenues
Revenues
439664000 USD
CY2014Q1 us-gaap Revenues
Revenues
625740000 USD
CY2014Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
362378000 USD
CY2013Q1 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
318740000 USD
CY2014Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
108850000 USD
CY2013Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
77260000 USD
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
81408000 USD
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
53030000 USD
CY2013Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
0 USD
CY2014Q1 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
0 USD
CY2013Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9804000 USD
CY2014Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
53920000 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
1952076000 USD
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
2211248000 USD
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
1245385000 USD
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
1406348000 USD
CY2014Q1 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
25365000 USD
CY2013Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
24601000 USD
CY2014Q1 us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
24192000 USD
CY2014Q1 us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
23428000 USD
CY2013Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
12491000 shares
CY2014Q1 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
13442000 shares
CY2013Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
109369000 shares
CY2014Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112151000 shares
CY2014Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
98709000 shares
CY2013Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
96878000 shares
CY2012Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
8600000 USD
CY2014Q1 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
17600000 USD
CY2013Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
16100000 USD
CY2013Q1 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
10100000 USD
CY2014Q1 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
30828000 USD
CY2013Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
23654000 USD
CY2014Q1 regn Accrued Sales Related Deductions And Royalties
AccruedSalesRelatedDeductionsAndRoyalties
94554000 USD
CY2013Q4 regn Accrued Sales Related Deductions And Royalties
AccruedSalesRelatedDeductionsAndRoyalties
66855000 USD
CY2014Q1 regn Amount Of Non Refundable Payment Received For Collaboration Agreement
AmountOfNonRefundablePaymentReceivedForCollaborationAgreement
25500000 USD
CY2014Q1 regn Costofmanufacturing
Costofmanufacturing
16099000 USD
CY2013Q1 regn Costofmanufacturing
Costofmanufacturing
1034000 USD
CY2013Q4 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
12815000 USD
CY2014Q1 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
12980000 USD
CY2014Q1 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
73694000 USD
CY2013Q4 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
76522000 USD
CY2014Q1 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
1060000 USD
CY2013Q4 regn Facility Lease Obligations Current
FacilityLeaseObligationsCurrent
939000 USD
CY2013Q4 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
184258000 USD
CY2014Q1 regn Facility Lease Obligations Noncurrent
FacilityLeaseObligationsNoncurrent
203380000 USD
CY2013Q1 regn Facilityleaseobligationrecognizedduringtheperiod
Facilityleaseobligationrecognizedduringtheperiod
0 USD
CY2014Q1 regn Facilityleaseobligationrecognizedduringtheperiod
Facilityleaseobligationrecognizedduringtheperiod
19400000 USD
CY2013Q1 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
325000 shares
CY2014Q1 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
401000 shares
CY2014Q1 regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentsmaybereceived200million
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentsmaybereceived200million
200000000 USD
CY2014Q1 regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived
500000000 USD
CY2014Q1 regn Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived5thtier
Levelsoftwelvemonthsalesatwhichsalesmilestonepaymentswerereceived5thtier
600000000 USD
CY2014Q1 regn Levelsoftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived1billion
Levelsoftwelvemonthssalesatwhichsalesmilestonepaymentsmaybereceived1billion
1000000000 USD
CY2014Q1 regn Numberof Paymentsthe Companymade
NumberofPaymentstheCompanymade
2
CY2014Q1 regn Numberofsalesmilestonepaymentsthe Companyreceived
NumberofsalesmilestonepaymentstheCompanyreceived
2
CY2014Q1 regn Other Collaboration Revenue
OtherCollaborationRevenue
125312000 USD
CY2013Q1 regn Other Collaboration Revenue
OtherCollaborationRevenue
14907000 USD
CY2014Q1 regn Period For Achieving Sales Target For Milestone Payment Rolling Basis
PeriodForAchievingSalesTargetForMilestonePaymentRollingBasis
P12M
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000872589
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS INC

Files In Submission

Name View Source Status
0001532176-14-000022-index-headers.html Edgar Link pending
0001532176-14-000022-index.html Edgar Link pending
0001532176-14-000022.txt Edgar Link pending
0001532176-14-000022-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regn-033114x10q.htm Edgar Link pending
regn-20140331.xml Edgar Link completed
regn-20140331.xsd Edgar Link pending
regn-20140331_cal.xml Edgar Link unprocessable
regn-20140331_def.xml Edgar Link unprocessable
regn-20140331_lab.xml Edgar Link unprocessable
regn-20140331_pre.xml Edgar Link unprocessable
regn-ex_102x03312014x10q.htm Edgar Link pending
regn-ex_311x03312014x10q.htm Edgar Link pending
regn-ex_312x03312014x10q.htm Edgar Link pending
regn-ex_32x03312014x10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending